Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 4/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.49 |
| ▸ | GLP1R | P43220 | 2/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477365 | 0.99 | OPRD1 (0.58) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL30299009 | 0.97 | OPRM1 (0.55) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL30376274 | 0.96 | OPRD1 (0.54) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL29378801 | 0.94 | BACE1 (0.54) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL31098023 | 0.91 | OPRD1 (0.60) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL29804647 | 0.90 | BACE1 (0.51) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL29674783 | 0.89 | OPRM1 (0.53) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL31038686 | 0.89 | OPRD1 (0.58) | OPRM1OPRD1OPRK1BACE1BACE2 | |
| SCHEMBL30407947 | 0.89 | OPRM1 (0.55) | OPRM1OPRD1OPRK1GLP1R | |
| SCHEMBL31257057 | 0.89 | OPRD1 (0.58) | OPRM1OPRD1OPRK1BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190938-A1 | GIP DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2024-06-13 | — | — | US | claimed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | claimed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | claimed |
| EP-4126921-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | claimed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | claimed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | claimed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | disclosed |
| EP-4126921-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | disclosed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | OPRM1 290/4885OPRD1 272/4885OPRK1 257/4885 |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | OPRM1 339/4885OPRD1 253/4885OPRK1 327/4885 |
| US-20240190938-A1 | GIP DERIVATIVES AND USES THEREOF | GIPR, GLP1R, GPR119 | OPRM1 861/4885OPRD1 1176/4885OPRK1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.